Crossmark Global Holdings Inc. Has $4.95 Million Position in Cencora, Inc. (NYSE:COR)

Crossmark Global Holdings Inc. reduced its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 54.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,781 shares of the company's stock after selling 21,681 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Cencora were worth $4,945,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. U.S. Capital Wealth Advisors LLC boosted its stake in shares of Cencora by 3.2% during the 1st quarter. U.S. Capital Wealth Advisors LLC now owns 8,509 shares of the company's stock worth $2,366,000 after acquiring an additional 260 shares during the period. Pacific Point Advisors LLC boosted its stake in shares of Cencora by 10.1% during the 1st quarter. Pacific Point Advisors LLC now owns 5,664 shares of the company's stock worth $1,575,000 after acquiring an additional 521 shares during the period. Raleigh Capital Management Inc. boosted its stake in shares of Cencora by 503.5% during the 1st quarter. Raleigh Capital Management Inc. now owns 344 shares of the company's stock worth $96,000 after acquiring an additional 287 shares during the period. Envestnet Asset Management Inc. boosted its stake in shares of Cencora by 1.7% during the 1st quarter. Envestnet Asset Management Inc. now owns 599,367 shares of the company's stock worth $166,678,000 after acquiring an additional 10,295 shares during the period. Finally, Penserra Capital Management LLC boosted its stake in shares of Cencora by 3.3% during the 1st quarter. Penserra Capital Management LLC now owns 3,355 shares of the company's stock worth $932,000 after acquiring an additional 108 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the transaction, the chairman directly owned 311,913 shares of the company's stock, valued at $91,271,982.06. This trade represents a 4.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,127 shares of company stock valued at $9,812,296 in the last three months. 10.80% of the stock is owned by insiders.

Cencora Price Performance

Shares of NYSE:COR traded up $2.10 during trading on Wednesday, reaching $300.13. 762,290 shares of the company traded hands, compared to its average volume of 1,505,783. The company's 50 day moving average is $291.57 and its two-hundred day moving average is $268.53. The firm has a market capitalization of $58.17 billion, a PE ratio of 34.82, a PEG ratio of 1.50 and a beta of 0.57. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The company's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $3.80 EPS. As a group, sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.73%. Cencora's dividend payout ratio (DPR) is currently 25.52%.

Analysts Set New Price Targets

Several research analysts have recently commented on COR shares. Jefferies Financial Group lifted their target price on Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a research note on Monday, June 30th. UBS Group boosted their price target on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Morgan Stanley set a $288.00 price target on Cencora in a research note on Tuesday, April 15th. Finally, Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $306.33.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.